Praetego has extensive experience in drug development

Extensive Technical and Operational Experience in Drug Development

Rachel Schindler, MD

Chief Medical Officer

Dr. Schindler is a neurologist, cognitive disorder expert, drug developer and medical strategist with over 20 years of pharmaceutical experience advising senior management of large and small companies, built upon extensive academic and patient care experience, across neurological and neuropsychiatric diseases. She is known for her unique blend of global experience in Clinical Development, Medical Affairs, Commercial Development, Business Development, Public Affairs and Policy, and Patient Advocacy. She spent over a decade as Pfizer’s medical lead for late-stage Neuroscience and Pfizer’s “Face of Alzheimer’s disease.” She was Chair of the Technical Review Committee, reviewing all protocols and advancement decisions and Co-Chair of the Neuroscience Strategy Team. She was a founding member and Chair of the Alzheimer’s Association Research Roundtable and has a track record of building high impact public-private consortia, consensus groups and collaborations. She has presented and spoken to decision makers and key influencers at high impact venues such as the European Medicines Agency (EMA), EU Parliament and the House of Lords, to enable drug development, effect changes in regulatory guidance, and improve patient care.

Praetego’s team led the discovery and development of the Amadorins. They are veterans of a rigorous and efficient drug development process.

Raja G. Khalifah, PhD

Chief Scientific Officer

Raja G. Khalifah, PhD, is a broadly trained chemist and biochemist who transitioned from academia to direct research at three startups (BioStratum, NephroGenex, Praetego) founded on discoveries from his research. He leverages extensive experience in medicinal chemistry and drug design, pharmacokinetics and drug metabolism, and preclinical and clinical studies. Dr. Khalifah is the primary co-inventor on sixteen (16) issued US patents in Amadorins and related fields.

Management

Pepper Landson

Co-founder / Chief Executive Officer

Pepper Landson has been a driving force in novel therapeutics for critical healthcare needs for three decades. Her efforts have impacted programs in Neurology (Rebif®), Oncology (Provenge®), Nephrology, and Infectious Disease. She has a proven record of creating value in early-stage companies. Pepper has successfully raised dilutive and non-dilutive funding and has experience in public markets. Her efforts supported a successful IPO in 2014 for a previous company. Combining her skills in business development and operations with an extensive drug development background, she is championing high impact treatments to protect brain health. She has worked exclusively on the Amadorin technology for neurodegenerative diseases for the last decade.